Movement Alert｜Gilead Sciences Pre-Market Rise 3.2%, Earnings Preview Keeps Focus on HIV and Oncology Momentum

Market Focus10-29 16:06

On October 29, Gilead Sciences rose 3.2% in Pre-Market Trading, trading at $162.5/share, with turnover of $167,500.

The move aligned with market focus ahead of the company’s quarterly results due later that day, with investors watching demand trends in core HIV products and oncology drug Trodelvy, alongside the pace of operating expenses.

Consensus expectations point to quarterly revenue of $7.797 billion, up 4.71% year over year, adjusted EPS of about $2.20, up 3.04%, and operating EBIT of $3.627 billion, up 4.26%. Recent analyst actions also supported sentiment, with JPMorgan lifting its target price to $170 earlier in the month and Jefferies raising its target price to $184. Separately, recent pipeline developments included a $1.28 billion cash acquisition of PepStar’s oral inflammation drug program, expanding Gilead Sciences’ inflammatory bowel disease portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment